A Blog from the Lymphoma Program at Weill Cornell Medicine and NewYork-Presbyterian
In an interview recorded during the 2016 American Society of Hematology Annual Meeting, Dr. Peter Martin discussed results from a phase 2 trial where researchers from the Fondazione Italiana Linfomi found that the addition of intermediate-dose of cytarabine to the first line treatment of rituximab and bendamustine led to a 91% response rate in elderly people with mantle cell lymphoma. This chemotherapy combination is known as RBAC500.
Click on the graphic above to watch this interview from the 2016 annual meeting of the American Society of Hematology, Lymphoma Program Director, Dr. John Leonard discusses results from the recently completed GALLIUM trial. In this trial researchers compared the safety and efficacy of either rituximab or obinutuzumab with chemotherapy followed by maintenance with the same agent as first-line therapy for patients with previously untreated follicular lymphoma.
In an interview with MDLinx during the 2016 American Society of Hematology Annual Meeting, Dr. Peter Martin discusses results from a phase I clinical trial designed to evaluate the safety and activity of ibrutinib plus palbociclib in people with previously treated MCL.
New Developments in Lymphoma 